The Japanese Patent Office has issued a decision to allow a patent covering the company's cancer vaccine technology for the treatment of cancer in humans and animals to be granted. The patent to be granted on Japanese Patent Application No. 2015-549902 entitled "Vaccines for the treatment or prevention of cancer and compositions for enhancing vaccine efficacy" will provide commercial rights in Japan through to 2033. A corresponding patent has been granted in Australia and corresponding patents are being pursued for grant in other key territories including the USA and Europe.
The technology uses a patient's own cancer cells combined with an immune-stimulant that is designed to re-educate the immune system to target cancer cells in both existing and new tumours.
The patent supports the company's RGSH4K (Human) and Kvax (Animal Health) clinical programs. RGSH4K is being tested in a phase 1 safety study in humans (ACTIVATE Trial) on a wide range of tumours being conducted through the Northern Cancer Institute at St Leonards, Sydney. Patients have been treated in all 3 dose levels without any safety concerns. The ACTIVATE trial is anticipated to complete recruitment and report on the study results in the first half of 2018.
Kvax has been the subject of a successful US study for the treatment of canine osteosarcoma. The results of the study showed that Kvax administered after limb amputation is safe and well tolerated and appears to confer increased progression free interval and improved survival compared to historically treated dogs with osteosarcoma treated with limb amputation only. Kvax is also the subject of a study for the treatment of canine lymphosarcoma in combination with chemotherapy being conducted at the Small Animal Specialist Hospital at North Ryde.
The technology was developed by researchers at the Bill Walsh Translational Cancer Research Laboratory, which is the research arm of the Medical Oncology Department at Royal North Shore Hospital at St Leonards, Sydney and part of the Kolling Institute of Medical Research. In a pre-clinical brain tumour model conducted by researchers at Bill Walsh Labs, vaccination led to remission rates of up to 60% and significantly extended survival in all vaccinated animals. Re-challenging animals in remission demonstrated 100% tumour rejection indicating acquired immunity.
Regeneus has in excess of 70 patents or patent applications across multiple patent families relating to its regenerative medicine products.
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
Company Secretary and Investor Relations